Sinovac

Corporate brand

Sinovac is a Chinese biopharmaceutical company known for developing, manufacturing, and commercializing vaccines against infectious diseases, including the inactivated COVID-19 vaccine CoronaVac.

Last updated October 9, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Sinovac, formally Sinovac Biotech Ltd., is a Chinese biopharmaceutical company headquartered in Beijing and focused on vaccines for human infectious diseases. Its business combines vaccine research and development, clinical and regulatory work, manufacturing, commercialization, and partnerships for distribution or local production. The company’s portfolio has included vaccines against hepatitis A, hepatitis B, influenza, Japanese encephalitis, polio, varicella, mumps, and other infectious diseases, although product availability and regulatory status vary by market and period. The operating foundation associated with the Sinovac group includes Sinovac Beijing, incorporated in 2001, and other production and operating entities in China. Sinovac expanded manufacturing capacity through arrangements involving Sinovac Dalian and through investment in production facilities. Earlier corporate filings described China as its principal market while also identifying Southeast Asia and other developing countries as target regions. The company’s commercial approach historically emphasized sales forces, professional and Chinese-language media, conferences, seminars, facility visits, and geographic expansion. Sinovac became internationally prominent during the COVID-19 pandemic through CoronaVac, an inactivated-virus vaccine developed for protection against COVID-19. China granted the vaccine conditional marketing authorization for adults in February 2021. Sinovac also entered supply, technology-transfer, and manufacturing arrangements with governments and pharmaceutical partners in countries including Brazil, Malaysia, Chile, and the Philippines. Its vaccine was used extensively in China and across Asia, Latin America, and other regions. The company reported that 260 million COVID-19 vaccine doses had been supplied globally by April 2021, with more than 60 percent delivered outside China; this was a company-reported operational figure rather than an independently audited brand-sales figure. CoronaVac also became part of China’s international health diplomacy and of political disputes about Chinese vaccines. Sinovac-sponsored visibility at the 2021 Copa América connected a vaccine manufacturer with mass-market sports marketing, an unusual positioning for a pharmaceutical brand. At the same time, the vaccine faced debate over clinical-data transparency, effectiveness in different populations and against changing variants, and the broader political context surrounding Chinese vaccine exports. Reuters later reported that a covert U.S. military social-media operation used fabricated accounts to disparage Chinese vaccines and other Chinese medical products, while other reporting described pro-China influence and promotional activity. These episodes are included as documented controversies surrounding the brand, not as findings that the vaccine itself was unsafe. Sinovac’s corporate history also includes public-market financing, expansion projects, a proposed going-private transaction, and a later private placement after that transaction was terminated. The company remains associated with vaccine development and manufacturing, but the supplied sources do not establish a definitive current parent, owner, public listing status, or complete present-day product catalogue.

History

Sinovac’s corporate and operating history is rooted in China’s vaccine manufacturing sector. Sinovac Beijing was incorporated in 2001, while other entities later associated with the group included Tangshan Yian and Sinovac Hong Kong. The company developed a business model centered on vaccines for infectious diseases and built capabilities spanning research, manufacturing, regulatory approval, and commercialization. Earlier filings identified China as its core market and Southeast Asia and other developing countries as important expansion targets. The company’s earlier commercial portfolio included Healive, a hepatitis A vaccine; Bilive, a combined hepatitis A and hepatitis B vaccine; and Anflu, an influenza vaccine. Its marketing plans called for expanding sales personnel, training representatives, increasing brand awareness through Chinese news and professional publications, and using conferences, seminars, and visits to company facilities to reach health professionals and institutional customers. Manufacturing expansion became a recurring strategic priority. In 2009 Sinovac agreed with Dalian Jin Gang Group to establish Sinovac Dalian, with the venture intended to research, develop, manufacture, and commercialize vaccines including mumps and varicella products. The venture was established in January 2010. Sinovac also completed an acquisition of buildings and land-use rights supporting a Changping production site near Beijing; the company said the site was intended to house two production lines and supporting functions, including capacity for influenza-vaccine production. Sinovac accessed U.S. public markets during its growth phase. Its common shares began trading on the OTC Bulletin Board in 2003 and moved to the American Stock Exchange, later NYSE Amex, in 2004 before trading on Nasdaq under SVA. The company conducted public offerings and other financings to support facilities, research, quality control, and new vaccine projects. In 2016, Sinovac received a preliminary proposal from Chairman and CEO Weidong Yin and SAIF Partners to take the company private. A definitive amalgamation agreement later valued the proposed transaction at approximately $401.8 million, but the board terminated the agreement in 2018. Sinovac then completed a private placement with Vivo Capital and Advantech Capital, reporting gross proceeds of $86.73 million for research, quality-control, and production facilities. Nasdaq halted trading in 2019 amid a proxy fight. The defining turning point came in early 2020, when Sinovac began developing CoronaVac, an inactivated COVID-19 vaccine. The product was evaluated in multiple countries and became central to China’s vaccine-export strategy. China issued conditional marketing authorization in February 2021. Supply and production arrangements followed in Brazil, Malaysia, Chile, the Philippines, and other markets. In Brazil, São Paulo state agreed to a major purchase and partnered with the Butantan Institute on local development and production. In Malaysia, Pharmaniaga combined procurement with plans for domestic manufacturing. Sinovac also worked with Alibaba Health on a platform intended to support appointment booking for vaccination. CoronaVac’s global use made Sinovac a highly visible pharmaceutical brand. The company reported hundreds of millions of doses supplied internationally, while public-health agencies and researchers assessed effectiveness across age groups, variants, dosing schedules, and booster strategies. The vaccine’s inactivated-virus technology was frequently contrasted with newer messenger-RNA platforms, and public discussion included questions about data transparency and differing real-world outcomes. Those debates varied by country and should not be reduced to a single universal efficacy claim. The company’s international profile was reinforced by sponsorship of the 2021 Copa América, where Sinovac branding appeared alongside major commercial sponsors. This represented a shift from conventional professional-healthcare promotion toward mass-audience marketing. CoronaVac also became entangled in geopolitical influence operations. Reuters reported a covert U.S. military campaign using fake accounts to undermine Chinese vaccines, while reporting and reference material also describe Chinese state-linked promotional or influence activity. Sinovac publicly criticized stigmatizing vaccine propaganda. The supplied material does not establish a complete current ownership structure or a definitive current listing status, so those fields remain unresolved.

2021
CoronaVac receives Chinese conditional authorization
[5]CoronaVac conditional authorization announcementbusinesswire.com
China’s NMPA granted CoronaVac conditional marketing authorization for adults.
2021
Copa América sponsorship
[4]Sinovac and football marketing analysistheconversation.com
Sinovac became an official sponsor of the 2021 Copa América, giving its vaccine brand prominent sports-media exposure.
2020
CoronaVac development and international partnerships
[14]CoronaVac development and international partnershipsreuters.com
Sinovac began COVID-19 vaccine development and entered supply or production discussions with international partners and governments.
2018
Going-private agreement terminated and private placement completed
[6]Sinovac 2018 private placement announcementsinovac.com
The board terminated the amalgamation agreement and Sinovac completed a private placement with Vivo Capital and Advantech Capital.
2016
Going-private proposal announced
[13]Going-private proposal announcedthepharmaletter.com
Chairman and CEO Weidong Yin and SAIF Partners proposed acquiring the outstanding shares of Sinovac.
2010
Sinovac Dalian established
[3]Sinovac annual and SEC filingssec.gov
A joint venture with Dalian Jin Gang Group was established to develop, manufacture, and commercialize vaccines.
2010
Changping capacity expansion completed
[12]Changping capacity expansion completedsinovac.com
Sinovac completed an acquisition supporting a Changping site planned for additional production lines and vaccine-manufacturing functions.
2004
Moves to the American Stock Exchange
[11]Shares begin OTC tradingsec.gov
The company’s shares began trading on the American Stock Exchange, later known as NYSE Amex.
2003
Shares begin OTC trading
[11]Shares begin OTC tradingsec.gov
Sinovac’s common shares began trading on the OTC Bulletin Board during the company’s public-market expansion.
2001
Sinovac Beijing incorporated
[3]Sinovac annual and SEC filingssec.gov
Sinovac Beijing, a key operating entity associated with the group, was incorporated in China.

Products and positioning

A China-based vaccine specialist combining domestic manufacturing scale with international supply, partnerships, and technology-transfer arrangements for infectious-disease vaccines.

COVID-19 vaccine · 2021
CoronaVac
CoronaVac is Sinovac’s inactivated-virus COVID-19 vaccine. It became the company’s best-known international product during the pandemic and was supplied through government procurement, bilateral arrangements, and local manufacturing partnerships. China granted it conditional marketing authorization for adults in February 2021. Its use and authorization have differed by country and over time.
Hepatitis A vaccine
Healive
Healive is Sinovac’s hepatitis A vaccine and one of the company’s established commercial products. Earlier corporate materials identified increasing its sales and revenues as a commercial objective, supported by domestic sales expansion and professional promotion.
Combined hepatitis A and B vaccine
Bilive
Bilive is a combined hepatitis A and hepatitis B vaccine listed in Sinovac’s earlier product portfolio. Company filings described planned commercialization and sales development for the product, but the supplied sources do not establish its current availability in specific markets.
Influenza vaccine
Anflu
Anflu is an influenza vaccine associated with Sinovac’s earlier commercial portfolio. The company’s expansion plans included increasing sales and using expanded production capacity to support influenza-vaccine manufacturing.
Childhood vaccines · 2010
Mumps and varicella vaccines
Sinovac Dalian was established with a mandate that included research, development, manufacturing, and commercialization of human vaccines such as mumps and varicella vaccines. The supplied sources do not provide a complete current brand-level catalogue for these products.

Controversies

2020
#ChinaAngVirus anti-Sinovac influence operation
Reuters reported that a covert U.S. military social-media operation used fabricated accounts to disparage Sinovac’s COVID-19 vaccine and other Chinese medical products, including by circulating claims about safety and pork-derived ingredients. The operation was reported to have targeted audiences in Southeast Asia, Central Asia, and the Middle East.
Source
2016
Chinese bribery probes
Reference material identifies Sinovac as having faced bribery probes in China. The supplied sources do not establish the full allegations, final findings, penalties, or responsible individuals.
Source

2021Copa América sponsorship
South America · International
Sinovac sponsored the 2021 Copa América, placing the vaccine brand in a mass-audience football environment and alongside other international sponsors. The campaign helped present COVID-19 vaccination as a widely consumed public-health product rather than only a specialist medical intervention.
Outcome. The campaign generated prominent brand visibility, including broadcast exposure during matches and interviews; the supplied source does not quantify commercial conversion or vaccination impact.
Source
2020Alibaba Health vaccination-booking platform
China
Sinovac partnered with Alibaba Health on a digital platform intended to allow people to book inoculation appointments for a potential COVID-19 vaccine.
Outcome. The source confirms the partnership but does not provide usage or outcome figures.
Source
2006Domestic vaccine brand-building program
China
Earlier company materials described a coordinated effort to expand the sales force, train representatives, raise awareness through Chinese news and professional publications, and use conferences, seminars, and facility visits to promote hepatitis and influenza vaccines.
Outcome. The materials present this as an intended commercial strategy; they do not provide a separately measured campaign outcome.
Source

Brand decisions

2021
Build regional production capacity in ChileStrategy
Background
Chile was among the countries that used Sinovac’s COVID-19 vaccine extensively, creating a basis for a regional manufacturing presence.
Action taken
Sinovac announced plans for a Chilean fill-and-finish plant.
Aftermath
The plan was intended to consolidate Sinovac’s Latin American presence, but the supplied source does not confirm the facility’s subsequent operating status.
Planned facility investment. US$60 million (2021 announcement)
Source
2020
Develop and scale CoronaVacProduct launch
Background
The COVID-19 pandemic created urgent demand for vaccines and an opportunity to expand Sinovac’s international manufacturing and supply network.
Action taken
Sinovac developed CoronaVac and pursued clinical, regulatory, procurement, and local-production arrangements in China and overseas.
Aftermath
CoronaVac became Sinovac’s most internationally visible product and was used across multiple regions, including Latin America and Southeast Asia.
Source
2018
Fund facilities and vaccine R&D through private placementStrategy
Background
After the proposed going-private transaction did not proceed, Sinovac’s board reviewed its standalone business plan and financing needs.
Action taken
The company completed a private placement with Vivo Capital and Advantech Capital and allocated the planned proceeds to research, quality-control, and production facilities.
Aftermath
The financing provided capital for continued vaccine development and manufacturing investment.
Gross private-placement proceeds. US$86.73 million (2018)
Source
2016
Pursue a going-private transactionM&A
Background
Chairman and CEO Weidong Yin and SAIF Partners proposed taking Sinovac private after the company had been publicly traded in the United States.
Action taken
Sinovac entered a definitive amalgamation agreement with Sinovac (Cayman) Limited and an acquisition subsidiary, with the proposed transaction valued at approximately $401.8 million.
Aftermath
The board terminated the amalgamation agreement in 2018, and the company pursued standalone financing instead.
Proposed transaction value. Approximately US$401.8 million (2016 proposed going-private transaction)
Source
2010
Expand manufacturing through Sinovac Dalian and ChangpingStrategy
Background
Sinovac sought additional capacity for vaccines including mumps, varicella, and influenza products as it expanded beyond its established facilities.
Action taken
It established Sinovac Dalian with Dalian Jin Gang Group and completed a Changping property acquisition intended to support new production lines.
Aftermath
The transactions created a platform for additional research, manufacturing, and commercialization capacity; the supplied sources do not document the full production outcome.
Source

Recent events

2021-11-13
Locally filled Sinovac vaccine begins supply to Myanmar[19]本地灌装科兴疫苗开始供应缅甸world.qianlong.com
Pharmaniaga said its locally filled Sinovac COVID-19 vaccine received an order from a Myanmar company and began shipments to supply the Myanmar market on November 13, marking the vaccine's first entry into an international market.
2021-01-19
Philippine FDA approves Sinovac vaccine clinical trial application[20]菲律宾 FDA 批准 Sinovac 疫苗临床试验申请gmanetwork.com
Reported: 2021-01-19
The Philippine Food and Drug Administration approved Sinovac Biotech’s application to conduct clinical trials of its COVID-19 vaccine in the Philippines.
2020-12-07
Sinovac announces plan to expand CoronaVac production capacity[21]Sinovac 宣布扩大 CoronaVac 产能的计划businesstimes.com.sg
Reported: 2020-12-06
Sinovac said it could manufacture 300 million vaccine doses annually and aimed to complete construction of a second production facility by the end of 2020, increasing annual Covid-19 vaccine production capacity to 600 million doses.
2020-12-07
Sinovac secures $515 million investment to support CoronaVac development and production[22]Sinovac获得5.15亿美元投资以支持CoronaVac研发和生产deccanherald.com
Reported: 2020-12-07
Sino Biopharmaceutical said a business unit would invest $515 million in Sinovac Life Sciences to help develop and produce CoronaVac. The investment would give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences.
2020-12-07
Sinovac secures approximately $500 million in funding for COVID-19 vaccine development[23]Sinovac获得约5亿美元资金用于新冠疫苗研发businesstoday.in
Reported: 2020-12-07
Sinovac Biotech said it had secured approximately $500 million in funding for COVID-19 vaccine development. The company identified Sino Biopharmaceutical Ltd. as the investor.

Sources25 sources

Cite this profile: Cite the canonical profile. /brand-wiki/sinovac · Editorial policy · How profiles are compiled